[Tumor marker in ovarian cancer]
review
public-domain-us
AI-generated summary
This review discusses CA125 as the most useful tumor marker for epithelial ovarian cancer, despite limitations in early-stage detection and monitoring, and briefly covers lysophosphatidic acid and inhibin.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The current role of tumor markers in the management of ovarian cancer is reviewed. The most useful tumor marker in epithelial ovarian cancer is still the antigen CA125. However, the level of this marker is modified by peritoneal irritation from endometriosis or inflammatory disease. Furthermore, the level is not elevated in nearly half of patients with the stage I disease, suggesting a limited value as a screening marker. In CA125 positive cases, the marker determination is a sensitive indicator in the early diagnosis of progressive disease in ovarian cancer. The lack of an effective second-line regimen, however, limits the value of the antigen as monitoring marker. Expectations for the new tumor markers lysophosphatidic acid and inhibin are also briefly discussed.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-21T06:08:07.822426+00:00
- pubmed
- last seen: 2026-05-13T22:13:13.417725+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine